Stock Market Reviews

ORIC (ORIC Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on ORIC (ORIC Pharmaceuticals, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
  Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and deep ctDNA reductions were observed in 76% of patients and ctDNA clearance was observed in 59% of patients, underscoring potential for long-term treatment and survival benefit PSA responses and ctDNA reductions were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide or with
  Nov 13, 2025 - $ORIC
• Could ORIC Pharmaceuticals' (ORIC) Pipeline Progress Reveal the Company’s Edge in Cancer Therapeutics?
  In recent weeks, ORIC Pharmaceuticals announced a peer-reviewed publication in Cancer Research highlighting the discovery and development of enozertinib, an investigational, brain-penetrant EGFR inhibitor for non-small cell lung cancer, and presented new preclinical data for ORIC-944 in prostate cancer at a major oncology conference. These milestones spotlight scientific momentum in the company’s oncology pipeline, from targeting complex cancer mutations to extending survival in preclinical...
  Nov 9, 2025 - $ORIC
• ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 3, 2025 (the “Grant Date”), ORIC granted a total of 18,400 non-qualified stock options and 3,000 restricted stock units to one new non-executive employee who began their employment with ORIC in October 2025. These inducement grant
  Nov 7, 2025 - $ORIC
• ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
  SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the publication of a peer-reviewed research paper in Cancer Research, a journal of the American Association for Cancer Research. The scientific paper details the discovery and development of enozertinib (formerly ORIC-114), a highly brain-penetra
  Nov 6, 2025 - $ORIC
• ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
  SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in November: Guggenheim’s 2nd Annual Healthcare Innovation Conference – Participating in a fireside chat on Tuesday, November 11, 2025, at 1:30 p.m. ET. Management will a
  Nov 4, 2025 - $ORIC
• ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
  SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics highlighting preclinical data that further illustrate the potential for ORIC-944, a potent and selective allosteric inhibitor of the polycomb repre
  Oct 27, 2025 - $ORIC
• BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
  ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
  Oct 22, 2025 - $ORIC
• We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
  We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
  Oct 4, 2025 - $ORIC
• Oric Pharmaceuticals Stock Scores RS Rating Upgrade
  Oric Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 80 to 83 Wednesday.   Looking For The Best Stocks To Buy And Watch? Start Here IBD's proprietary rating tracks share price movement with a 1 (worst) to 99 (best) score.
  Sep 17, 2025 - $ORIC
• This ORIC Pharmaceuticals Insider Increased Their Holding In The Last Year
  Insiders were net buyers of ORIC Pharmaceuticals, Inc.'s ( NASDAQ:ORIC ) stock during the past year. That is, insiders...
  Aug 24, 2025 - $ORIC